 -- Collaboration aims to evaluate the potential of AllocetraTM in combination with immune-checkpoint inhibitors in solid cancer patients that do not respond to stand-alone checkpoint inhibitor therapies -- Nes Ziona, Israel, March 01, 2021 GLOBE NEWSWIRE -- Enlivex Therapeutics Ltd. Nasdaq: ENLV, the Company, a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors, and Mount Sinai Health System, one of the worlds leading academic health systems, today announced a new research collaboration for the development of clinical strategies for AllocetraTM with checkpoint inhibitors. AllocetraTM is a macrophage-reprogramming immunotherapy product candidate currently in clinical development by Enlivex for the potential treatment of life-threatening immune-mediated diseases. 